This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Dr. Aron Tendler, CMO of Brainsway®, is interviewed on Deep TMS as a treatment option for depression, as well as the conncetions between depresison and ADD. Listen to the interview here.